Long-Term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated with Gene-Modified Cells
Long-Term Follow-up Study for Participants of Kite-Sponsored Gene-Modified Therapy Studies
Sponsor: Kite Pharma, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAU1511
U.S. Govt. ID: NCT05041309
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to monitor you for any delayed side effects that may possibly be related to the experimental gene-modified therapy product you received in the Kite-sponsored study for Axicabtagene ciloleucel (axi-cel). The main study does not involve treatment. In the re-treatment portion, you will be provided access to a second course of treatment with lymphodepleting chemotherapy and axi-cel. Axi-cel is manufactured using your own blood cells. If you meet the requirements for the retreatment part of this study, the study doctor will confirm if leftover product from your participation in the previous Kite-sponsored study can be used for your second dose.
Ran Reshef, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Did you participate in a Kite-sponsored, gene therapy parent study? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator